Clinical trial Recruiting at 1 site Observational Ages 18 to 45 Women only

How attitudes toward artificial intelligence relate to anxiety and quality of life in women receiving infertility treatment

Official title: The Relationship Between Quality of Life, Anxiety Levels, and Attitudes Toward Artificial Intelligence Among Women Undergoing Infertility Treatment

Run by Acibadem University · NCT07308561 · Data updated 2026-11-12

This study will test whether women's attitudes toward artificial intelligence are linked to their anxiety and quality of life while undergoing infertility treatment.

More Anxiety trials

Quick facts

Study typeObservational
Ages18 Years to 45 Years
SexWomen only
Enrollment191 (estimated)
SponsorAcibadem University
Academic / other
Locations1 site (Istanbul, Ataşehir)
StatusRecruiting
StartedOctober 23, 2025
Main results expectedOctober 23, 2026
Study endsOctober 23, 2026
Registry record updatedDecember 29, 2025
Trial IDNCT07308561 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–45 with primary or secondary infertility who are currently receiving infertility treatment (IUI, IVF, or ICSI) at Acıbadem and who can read and speak Turkish are ideal candidates.

Probably not a fit

Women who are not undergoing infertility treatment, those with diagnosed psychiatric disorders, non-Turkish speakers, or those unable to attend the Istanbul site are unlikely to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, questionnaire-based study of women aged 18–45 receiving infertility treatments (IUI, IVF, ICSI) at Acıbadem Health Group in Istanbul. Participants who speak Turkish and do not have diagnosed psychological disorders will complete validated measures of anxiety, quality of life, and attitudes toward AI. Researchers will analyze associations between AI attitudes and psychosocial outcomes and explore whether these relationships differ by treatment modality or demographic factors. The study aims to identify patterns that could inform communication and support strategies in fertility care.

Why it matters

Potential benefit: If successful, the findings could help tailor patient communication and support to reduce anxiety and improve quality of life while increasing appropriate acceptance of AI tools in infertility care.

How similar studies have gone: Previous research shows AI can support clinical decision-making in reproductive medicine and that anxiety affects quality of life, but direct study of how attitudes toward AI influence psychosocial outcomes in infertility is relatively limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women aged 18-45 years diagnosed with infertility (primary or secondary infertility).
* Women undergoing infertility treatment and those who have experienced various treatment modalities (IUI, IVF, ICSI).
* Women who voluntarily agree to participate in the study.
* Women who are able to understand and speak Turkish.

Exclusion Criteria:

* Women with diagnosed psychological disorders (e.g., clinical depression, anxiety disorders).
* Women who are not undergoing infertility treatment.

Where it's running

  • Acıbadem Health Group
    Istanbul, Ataşehir, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.